H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Check-Cap (NASDAQ: CHEK) today and set a price target of $14. The company’s shares closed yesterday at $4.40, close to its 52-week low of $3.12.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.8% and a 41.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Check-Cap has an analyst consensus of Moderate Buy, with a price target consensus of $14.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24 and a one-year low of $3.12. Currently, Check-Cap has an average volume of 800.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Check-Cap Ltd. clinical stage medical diagnostics company, which engages in developing gastrointestinal imaging devices. It develops capsule-based system that utilizes low-dose X-rays to detect polyps, masses and colorectal cancer screening. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
Read More on CHEK:
